Physician profile
David L Christopherson
NPI 1184611485
$7,900.92
in general payments reported to CMS, 2019-2025
26 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $27.62 · 2021: $767 · 2022: $2,019 · 2023: $2,273 · 2024: $2,051 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,718.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.07 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $911.28 | 2020-2025 | |
| Novo Nordisk INC | $740.09 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $695.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $652.56 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $451.97 | 2021-2025 | |
| Abbott Laboratories | $405.78 | 2021-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $333.94 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $265.58 | 2022 | |
| Exact Sciences Corporation | $255.13 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $234.52 | 2022-2024 | Quviviq |
| Esperion Therapeutics, INC. | $217.99 | 2021 | |
| Glaxosmithkline, LLC. | $204.78 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lundbeck LLC | $204.73 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $199.10 | 2023-2024 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $147.24 | 2019-2023 | |
| Eisai INC. | $140.60 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.71 | 2022-2024 | Trintellix |
| Shield Therapeutics INC | $107.76 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.53 | 2022-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $81.94 | 2024 | Voquezna |
| Amgen INC. | $40.51 | 2024-2025 | Evenity, Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.18 | 2024-2025 | Caplyta |
| Verity Pharmaceuticals INC. | $27.96 | 2024 | Tlando |
| Redhill Biopharma INC. | $26.70 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.05 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Christopherson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.